AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- S&P 500, Dow set for lower open after jobs report fuels rate-hike bets
- US nonfarm payrolls surge in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil heads for weekly gain as US-Iran fighting resumes; diesel hits record high
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
BMO Capital Reiterates Outperform Rating on Amgen (AMGN)
November 12, 2024 4:24 PM ESTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $362.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "When has three patients worth of data ever been the 'be all and end all'? Context matters, and while this MariTide data... More
Barclays Reiterates Equalweight Rating on Amgen (AMGN)
November 12, 2024 4:23 PM ESTBarclays analyst Carter Gould reiterated an Equalweight rating and $315.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "We reviewed the supplemental MariTide (AMG133) phase 1 data, highlighted by (1) BMD loss (as measured by DEXA scan across femur and hip) at higher doses (420mg), and (2) notable heart rate excursions (25bpm at the 280mg dose). While far from... More
Jefferies on Amgen (AMGN): 'Thoughts on Phase I bone data for AMG-133 - seems non-issue'
November 12, 2024 3:44 PM ESTJefferies analyst Michael Yee reiterated a Buy rating and $380.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "We reviewed public data from Phase I AMG-133 showing add'l measurements of BMD (bone density) from obesity pts - which could be interpreted... More
Cantor Fitzgerald Locates Data on Amgen (AMGN) Hidden in Tables for MariTide's Data
November 12, 2024 2:48 PM ESTCantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating and $405.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "We just came across a new piece of information from MariTide's Ph1, and we found a big surprise... The supplemental appendix file seems to show bone mineral... More
